NVO
Novo Nordisk A/S
NVO has a slight edge over STXS overall, supported by stronger fundamentals and lower modeled downside.
STXS
Stereotaxis, Inc.
STXS offers stronger modeled upside, but that advantage does not outweigh its weaker overall profile.
NVO Fundamentals
| Metric | Status |
|---|---|
| Healthy | |
| Strong | |
| Stable | |
| Healthy |
NVO's revenue, profitability and balance sheet are currently healthy, and its cash flow is stable.
STXS Fundamentals
| Metric | Status |
|---|---|
| Under pressure | |
| Under pressure | |
| Weak | |
| Unavailable |
STXS's revenue, profitability and cash flow are currently under pressure. There isn't enough data to rate its balance sheet.
NVO PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Current | 10x | $40.65 | — |
| Cheap | 14x | $53.56 | +32% |
| Fair | 27x | $103 | +154% |
| Expensive | 39x | $152 | +273% |
Historical ranges are pointers, not guarantees.
NVO's PE is 10x, but its earnings don't support one, so it isn't a reliable read right now.
STXS PE Valuation
STXS has no meaningful PE right now: it lost money over the past year.
NVO Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Stable | |
| Growth | |
| Weakening | |
| Limited | |
| Low |
Analysts expect NVO's revenue to grow, but its profitability to weaken. However, they disagree widely on these estimates.
STXS Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Losses shrinking | |
| Growth | |
| Strongly improving | |
| Limited | |
| Moderate |
STXS has the edge over NVO on the outlook, with more favorable earnings and profitability expectations.
NVO Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q2 2026 | $3.89 | +4.9% |
| Q1 2026 | $4.07 | +17% |
| Q4 2025 | $3.42 | +1.8% |
| Q3 2025 | $3.47 | +10% |
| Q2 2025 | $3.71 | +24% |
| Q1 2025 | $3.49 | +18% |
| Q4 2024 | $3.36 | +21% |
| Q3 2024 | $3.15 | +27% |
NVO has the edge over STXS on earnings quality, reporting a profit while its opponent remains loss making.
STXS Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q2 2026 | -$0.24 | +$0.05 |
| Q1 2026 | -$0.24 | +$0.07 |
| Q4 2025 | -$0.25 | +$0.05 |
| Q3 2025 | -$0.28 | -$0.01 |
| Q2 2025 | -$0.29 | -$0.03 |
| Q1 2025 | -$0.31 | -$0.05 |
| Q4 2024 | -$0.30 | -$0.03 |
| Q3 2024 | -$0.27 | $0.00 |
STXS is still losing money, but less than at its worst: $0.24 per share over the past year, against $0.31 at its worst in early 2025.
NVO Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q2 2026 | $11.7B | +2.1% |
| Q1 2026 | $14.4B | +24% |
| Q4 2025 | $11.8B | -7.6% |
| Q3 2025 | $11.1B | +5.1% |
| Q2 2025 | $11.4B | +13% |
| Q1 2025 | $11.6B | +19% |
| Q4 2024 | $12.7B | +30% |
| Q3 2024 | $10.6B | +21% |
NVO has the edge over STXS on sales, with more consistent year-over-year improvement.
| Quarter | Margin | YoY |
|---|---|---|
| Q2 2026 | 34% | -9 points |
| Q1 2026 | 62% | +12 points |
| Q4 2025 | 40% | -2.8 points |
| Q3 2025 | 32% | -16 points |
| Q2 2025 | 44% | +5.4 points |
| Q1 2025 | 50% | +1 points |
| Q4 2024 | 43% | +2.2 points |
| Q3 2024 | 47% | +1.6 points |
NVO has the edge over STXS on profitability, with a higher operating margin.
STXS Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q2 2026 | $7.7M | -13% |
| Q1 2026 | $6.3M | -16% |
| Q4 2025 | $8.6M | +36% |
| Q3 2025 | $7.5M | -19% |
| Q2 2025 | $8.8M | +95% |
| Q1 2025 | $7.5M | +8.6% |
| Q4 2024 | $6.3M | +39% |
| Q3 2024 | $9.2M | +18% |
STXS's revenue has slid since its 2024 peak: $8M last quarter, down 13% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q2 2026 | -60% | -14 points |
| Q1 2026 | -95% | -16 points |
| Q4 2025 | -65% | +55 points |
| Q3 2025 | -88% | -19 points |
| Q2 2025 | -45% | +89 points |
| Q1 2025 | -79% | -10 points |
| Q4 2024 | -120% | -4.1 points |
| Q3 2024 | -69% | +3.3 points |
STXS's operating margin was −60% last quarter, down 14 points from the same quarter a year ago.
NVO Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q2 2026 | $6.3B | +73% |
| Q1 2026 | $1.8B | +20% |
| Q4 2025 | -$5.4B | -$4.7B |
| Q3 2025 | $4.6B | -2.1% |
| Q2 2025 | $3.6B | -34% |
| Q1 2025 | $1.5B | +89% |
| Q4 2024 | -$632.6M | +$390.5M |
| Q3 2024 | $4.7B | +3.3% |
NVO has the stronger cash trend. Its trailing FCF is down 14% versus its history, compared with STXS at down 101%.
STXS Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q1 2026 | -$3.5M | -$1.7M |
| Q4 2025 | -$4M | -420% |
| Q3 2025 | -$4.2M | +$135K |
| Q4 2024 | $1.3M | +$3.7M |
| Q3 2024 | -$4.3M | -$3.4M |
| Q4 2023 | -$2.4M | +$482K |
| Q3 2023 | -$977K | +$1.8M |
| Q2 2023 | -$2.9M | -$1.2M |
STXS has burned cash in almost every quarter: −$16M over the past year, against −$7M the year before.
NVO Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | -0.3% | -12.9M shares |
| 1 year | -0.2% | -11M shares |
| 3 years | -1.5% | -66.8M shares |
| 5 years | -3.8% | -177M shares |
| Available history | -6.5% | -311M shares |
NVO has the edge over STXS on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q2 2026 | $520M |
| Q1 2026 | $356.7M |
| Q4 2025 | — |
| Q3 2025 | — |
| Q2 2025 | — |
| Q1 2025 | $206.3M |
| Q4 2024 | $1.1B |
| Q3 2024 | $357.4M |
NVO spent $877M buying back its own shares over the past year, down 48% from the year before.
STXS Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +1.2% | +1.1M shares |
| 1 year | +14% | +12.1M shares |
| 3 years | +23% | +19M shares |
| 5 years | +32% | +24.5M shares |
| Available history | +56% | +35.7M shares |
STXS has 100M diluted shares, up 14% from a year ago.
NVO Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q2 2026 | 0.5x | Very low |
| Q1 2026 | 0.7x | Very low |
| Q4 2025 | 0.6x | Very low |
| Q3 2025 | 0.4x | Very low |
| Q2 2025 | 0.5x | Very low |
| Q1 2025 | 0.5x | Very low |
| Q4 2024 | 0.6x | Very low |
| Q3 2024 | -0.0x | Very low |
NVO's net debt is less than a year of its operating earnings (EBITDA).
STXS Net Leverage
STXS's operating earnings (EBITDA) were negative over the past year, so its debt can't be measured against them.
NVO Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 43.0 | Neutral |
| Stochastic | 27.0 | Neutral |
NVO's weekly RSI is 43 (neutral) and its Stochastic is 27 (neutral).
STXS Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 31.1 | Neutral |
| Stochastic | 18.5 | Oversold |
STXS's weekly RSI is 31 (neutral) and its Stochastic is 18 (oversold).
NVO PE vs Healthcare Sector
| Metric | NVO | Sector median | Relative |
|---|---|---|---|
| PE | 10x | 26x | 60% below |
| PE % | 6 | 29 | 23 pts below |
NVO is trading at 10x earnings, a 60% discount to the Healthcare sector's median of 26x, though its earnings don't support one.
STXS PE vs Healthcare Sector
STXS has no meaningful PE right now: it lost money over the past year.
NVO Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $39.2 | 3.7% above |
| 20 week MA | $43.9 | 7.4% below |
| 50 week MA | $45.3 | 10% below |
| 100 week MA | $56.3 | 28% below |
| 200 week MA | $80.7 | 50% below |
NVO has the edge over STXS on trend strength, trading above more of its moving averages.
STXS Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $1.05 | 19% below |
| 20 week MA | $1.28 | 34% below |
| 50 week MA | $1.76 | 52% below |
| 100 week MA | $2.05 | 59% below |
| 200 week MA | $2.02 | 58% below |
STXS is in a downtrend: it's below all five of its weekly moving averages, and 58% below its 200-week average.
NVO Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $29.1 | $34.7 | +19% |
| 2021 | $34.7 | $54.2 | +56% |
| 2022 | $54.2 | $67.0 | +24% |
| 2023 | $67.0 | $103.5 | +54% |
| 2024 | $103.5 | $87.4 | -16% |
| 2025 | $87.4 | $52.4 | -40% |
| 2026 YTD | $52.4 | $40.7 | -22% |
NVO has the edge over STXS on returns for 2026, with the stronger performance.
STXS Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $5.03 | $5.14 | +2.2% |
| 2021 | $5.14 | $6.26 | +22% |
| 2022 | $6.26 | $2.03 | -68% |
| 2023 | $2.03 | $1.75 | -14% |
| 2024 | $1.75 | $2.29 | +31% |
| 2025 | $2.29 | $2.46 | +7.4% |
| 2026 YTD | $2.46 | $0.85 | -65% |
STXS is down 65% so far in 2026, after finishing higher in four of the previous six years.